Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $70 from $80 and keeps an Overweight rating on the shares. The firm notes that Phase 1 ATTR-CM data for nex-z compare well vs. historical data shown by silencers and stabilizers, despite having a greater proportion of patients with more severe disease. Wells thinks this should bode well for Phase 3 success.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target raised to $91 from $88 at Chardan
- Intellia Therapeutics price target lowered to $60 from $70 at Oppenheimer
- Intellia Therapeutics price target lowered to $55 from $76 at Barclays
- Intellia Therapeutics Reports Q3 2024 Financial Progress
- Intellia Therapeutics price target lowered to $40 from $41 at JonesResearch